CD8A and neoplasm: Based on the findings of the kinetic analysis of tumor-infiltrating and circulating immune cells, they showed that CD8-T cells with a tissue-residency program were early responders to ICI and that neoadjuvant ICI enhanced local and systemic tumor immunity.